Core Viewpoint - WuXi AppTec (2126.HK) has announced that the National Medical Products Administration of China has officially accepted its supplementary application for the post-marketing use of Beiduo Da® with domestically produced viral vectors, which is strategically significant for the company [1] Group 1: Company Strategy - The use of lentiviral vectors is crucial as it is one of the most important and costly raw materials for cell therapy products [1] - The domestic substitution of lentiviral vectors is expected to stabilize the supply for commercial products and clinical development, leading to a significant reduction in production costs [1] - Lower costs will enhance the company's ability to compete in commercialization and insurance negotiations, potentially increasing the commercial value of Beiduo Da® [1]
药明巨诺：国家药监局已正式受理其倍诺达新增使用国产病毒载体的上市后补充申请